



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Antitumor agent-153

Cat. No.:	HY-163518
Molecular Formula:	C <sub>16</sub> H <sub>8</sub> N <sub>2</sub> O <sub>6</sub>
Molecular Weight:	324.24
Target:	E1/E2/E3 Enzyme
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity. <sup>[12][1]</sup>								
<b>In Vitro</b>	<p>Antitumor agent-153 has an IC<sub>50</sub> of 5.86 μM on U2O cells and completely inhibits their proliferation at 30 μM<sup>[1]</sup>. Reduced H2AK119ub1 levels disrupt tumor development and cancer cell growth. Antitumor agent-153 (24-96 μM; 1 h) can significantly reduce H2AK119ub1 levels in U2O cells in a dose-dependent manner<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>U2O cells</td> </tr> <tr> <td>Concentration:</td> <td>6 μM, 12 μM, 24 μM, 48 μM, 96 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 h</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased H2AK119ub1 levels in cells in a dose-dependent manner (24-96 μM).</td> </tr> </table>	Cell Line:	U2O cells	Concentration:	6 μM, 12 μM, 24 μM, 48 μM, 96 μM	Incubation Time:	1 h	Result:	Significantly decreased H2AK119ub1 levels in cells in a dose-dependent manner (24-96 μM).
Cell Line:	U2O cells								
Concentration:	6 μM, 12 μM, 24 μM, 48 μM, 96 μM								
Incubation Time:	1 h								
Result:	Significantly decreased H2AK119ub1 levels in cells in a dose-dependent manner (24-96 μM).								

### REFERENCES

[1]. Ni S, et al. Identification of a novel histone H2A mono-ubiquitination-inhibiting cell-active small molecule. *Bioorg Med Chem Lett*. 2024 Jun 1;105:129759.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA